Related Experiment Video
Updated: Oct 9, 2026

Detecting the Lyme Disease Spirochete, Borrelia Burgdorferi, in Ticks Using Nested PCR
Published on: February 4, 2018
Azithromycin versus penicillin V for the treatment of early Lyme borreliosis
K Weber1, B Wilske, V Preac-Mursic
1Abteilung für Mikrobiologie, Max von Pettenkofer Institut, Universität München, Germany.
Abstract:
In a randomized multicenter therapeutic trial, 32 patients with erythema migrans received oral azithromycin 500 mg once daily and 33 patients received phenoxymethylpenicillin (penicillin V) 1 million U three times daily for 10 days. Follow-up was for a median of 17 (range 3-32) months. Four weeks after initiation of therapy, 20 (62%) patients given azithromycin and 17 (51%) patients given penicillin V were completely free of all signs and symptoms and did not develop new ones subsequently (no significant difference). Three months after initiation of therapy, the corresponding figures were 25 (78%) azithromycin and 28 (85%) penicillin V recipients (no significant difference). There were only minor sequelae such as arthralgia, headache, fatigue, stiff neck and dysesthesia. Azithromycin led to a significantly faster resolution of the erythema migrans than penicillin V (p < 0.001). Significantly more patients with more severe compared with mild initial disease had an elevated IgM antibody titer prior to therapy (p < 0.001). Usually mild to moderate side effects occurred in 12 patients given azithromycin and five patients given penicillin V (p < 0.05). Azithromycin appears to be as effective as penicillin V for the treatment of early Lyme borreliosis and it seems to clear the erythema migrans more promptly.
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Tonsillitis II: Management
Acute Pyelonephritis II: Diagnostic Studies and Management
Production of Antibiotics
Rocky Mountain Spotted Fever
Inhibitors of Gram-positive Cell Wall Synthesis

